ABSTRACT

Vildagliptin is approved in 2007 by USFDA. Vildagliptin s- l-[n-(3-hydroxy-1-adamantyl) glycyl] pyrrolidine-2- carbonitrile is oral anti-diabetic drug of the new potent dipeptidyl peptidase-4 inhibitor category of antidiabetic medicine. The present work category theeasy, accurate, precise analytical HPLC method. This paper could be a review analyticalHPLC techniques that are the widely-used in determination common provision issues. In these review involve information about HPLC method development like mobile phase, mobile phase ratio, column, retention time, flow rate and wavelength of UV detector, run time and Validation parameter is Linearity, percentage recovery, limit of detection and limit of quantification. Pharmaceutical analysis plays an important role in quality assurance as internal control of pure and pharmaceutical dosage form. Analytical method development has become the important activity of study. Keywords: Vildagliptin, Drug profile, Pharmacology, Pharmacokinetic, Analytical HPLC Method
Publication date: 25/01/2022

https://ijbpas.com/pdf/2022/January/MS_IJBPAS_2022_JAN_SPCL_2_2018.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.1.2018